• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Drugs in Development

To test new drugs and treatments for ALS/MND, researchers and pharmaceutical companies must perform clinical trials. A clinical trial is a therapeutic or observational research study to test whether a new drug or therapy is safe and effective for use in humans. Prior to any clinical trial, a drug must pass through a series of steps. 

For ALS/MND, there are many potential drugs and therapies currently undergoing clinical trials. Clinical trials are essential to new drug approvals. However, enrollment in a clinical trial should always be voluntary. People living with ALS/MND must consent prior to enrollment and have the right to know all pertinent details surrounding the trial.

Clinical Trial Information

Here are links to databases of known clinical trials for ALS/MND.

  • ALS/MND Clinical Trial Navigator: The ALS Therapy Development Institute created the ALS Trial Navigator is a comprehensive resource for making informed decisions about participating in ALS/MND clinical trials. Use this innovative tool learn about clinical trials and get a personalized list of ALS/MND trials based on your eligibility and preferences. (Language: English)
  • ALS International Clinical Trial Database: The Associazione conSLAncio Onlus created the ALS/MND International Clinical Trial Database. Built on a multi-lingual website, this features users to view the current status of clinical trials taking place at sites in, or close to, Italy. Each trial is linked to the official trial registry where users can directly access study objectives, eligibility criteria and study contacts. (Language: Italian)
  • HEALEY ALS Platform Trial: The HEALEY ALS Platform Trial aims to accelerate the process of drug development and the path for effective treatment for ALS/MND by testing multiple drugs simultaneously and adaptively. This design has been seen to be successful in cancer trials. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to receive either the study drug or placebo. New regimens will be continuously added as new investigational products become available. The trial is recruiting in the United States only and will enroll additional participants as each new regimen is available. (Language: English)

Information on Drugs in Clinical Trial

Here are briefing notes from the International Alliance’s Scientific Advisory Council on drugs and therapies currently being researched.

SPG302

Masitinib

Pridopidine

NP001

Neuronata-R / Lenzumestrocel

Ulefnersen

NurOwn

CNM-Au8

AstroRx

ILB

PrimeC

SOD1-Targeted Therapies & Trials

Regulatory T Cell Enhancing Therapies

C9orf72 Therapies and Trials

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • Jon Newsome, USA

    Jon Newsome, USA

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Armando González Gómez, Colombia

    Armando González Gómez, Colombia

  • Liam Dwyer, England

    Liam Dwyer, England

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Len Johnrose, England

    Len Johnrose, England

  • Michael Lee, Australia

    Michael Lee, Australia

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Jan Zuring, Netherlands

    Jan Zuring, Netherlands

  • Joy Blakeley, Australia

    Joy Blakeley, Australia

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Ali Var, Turkey

    Ali Var, Turkey

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Mark Miller, UK

    Mark Miller, UK

  • Purningam Jacob, India

    Purningam Jacob, India

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Anna Barrow, UK

    Anna Barrow, UK

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • David Bishop, UK

    David Bishop, UK

  • Glen Elison, USA

    Glen Elison, USA

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Animesh Kumar, India

    Animesh Kumar, India

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login